AbbVie terminates Alector collaboration agreement

Alector (NASDAQ:ALEC) said AbbVie (NYSE:ABBV) has sent written notice that it is terminating the TREM2 program, the last remaining program under their development agreement.

Termination of the agreement will be effective 30 days from receipt of the termination letter, Alector (ALEC) said